The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Blood

• Publication date

  2009-05-07

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/blood-2008-09-175430PMID 19190247PMCID PMC2680369
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Total synthesis of the potent anticancer Aglaia metabolites (-)-silvestrol and (-)-episilvestrol and the active analogue (-)-4'-desmethoxyepisilvestrol.

  2009cited by this paper
• Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium.

  2008cited by this paper
• Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers.

  2008cited by this paper
• Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model.

  2008cited by this paper
• Connecting endoplasmic reticulum stress to autophagy by unfolded protein response and calcium

  2007cited by this paper
• Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia.

  2007cited by this paper
• Total synthesis of (-)-episilvestrol and (-)-silvestrol.

  2007cited by this paper
• Enantioselective synthesis of the complex rocaglate (-)-silvestrol.

  2007cited by this paper
• Translational Repression of MCL-1 Couples Stress-induced eIF2α Phosphorylation to Mitochondrial Apoptosis Initiation*

  2007cited by this paper
• Mcl-1 Is a Relevant Therapeutic Target in Acute and Chronic Lymphoid Malignancies: Down-Regulation Enhances Rituximab-Mediated Apoptosis and Complement-Dependent Cytotoxicity

  2007cited by this paper
• Emerging therapeutic options for Philadelphia-positive acute lymphocytic leukemia

  2007cited by this paper
• Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.

  2007cited by this paper
• The traditional Chinese herbal compound rocaglamide preferentially induces apoptosis in leukemia cells by modulation of mitogen‐activated protein kinase activities

  2007cited by this paper
• Silvestrol, a potential anticancer rocaglate derivative from Aglaia foveolata, induces apoptosis in LNCaP cells through the mitochondrial/apoptosome pathway without activation of executioner caspase-3 or -7.

  2007cited by this paper
• Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins

  2006cited by this paper
• B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia.

  2006cited by this paper
• Methylation of the IL-12Rβ2 Gene as Novel Tumor Escape Mechanism for Pediatric B-Acute Lymphoblastic Leukemia Cells

  2006cited by this paper
• Methylation of the IL-12Rbeta2 gene as novel tumor escape mechanism for pediatric B-acute lymphoblastic leukemia cells.

  2006cited by this paper
• Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia.

  2006cited by this paper
• In vivo control of acute lymphoblastic leukemia by immunostimulatory CpG oligonucleotides.

  2006cited by this paper
• Infectious complications of chronic lymphocytic leukemia.

  2006cited by this paper
• Silvestrol regulates G2/M checkpoint genes independent of p53 activity.

  2006cited by this paper
• Potential of cyclopenta[b]benzofurans from Aglaia species in cancer chemotherapy.

  2006cited by this paper
• Rocaglamide Derivatives Are Immunosuppressive Phytochemicals That Target NF-AT Activity in T Cells

  2005cited by this paper
• Apoptosis-based therapies for hematologic malignancies.

  2005cited by this paper
• Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death.

  2005cited by this paper
• Bodyguards and assassins: Bcl‐2 family proteins and apoptosis control in chronic lymphocytic leukaemia

  2005cited by this paper
• Silvestrol and episilvestrol, potential anticancer rocaglate derivatives from Aglaia silvestris.

  2004cited by this paper
• CD107a as a functional marker for the identification of natural killer cell activity.

  2004cited by this paper
• The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells

  2004cited by this paper
• Granulocyte Macrophage Colony-stimulating Factor Signaling and Proteasome Inhibition Delay Neutrophil Apoptosis by Increasing the Stability of Mcl-1*

  2004cited by this paper
• Adult acute lymphoblastic leukaemia.

  2004cited by this paper
• Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.

  2004cited by this paper
• Mcl-1 Regulation and Its Role in Multiple Myeloma

  2004cited by this paper
• Interleukin-4-induced apoptosis entails caspase activation and suppression of extracellular signal-regulated kinase phosphorylation.

  2003cited by this paper
• Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance.

  2003cited by this paper
• Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein.

  2003cited by this paper
• Bisindolylmaleimide IX is a potent inducer of apoptosis in chronic lymphocytic leukaemic cells and activates cleavage of Mcl-1

  2003cited by this paper
• Transcriptional and translational control of Mcl-1 during apoptosis.

  2003cited by this paper
• Rocaglamide derivatives are potent inhibitors of NF-kappa B activation in T-cells.

  2002cited by this paper
• MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis

  2002cited by this paper
• Rocaglamide Derivatives Are Potent Inhibitors of NF-κB Activation in T-cells*

  2002cited by this paper
• Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors.

  2002cited by this paper
• Myeloid cell factor-1 is a critical survival factor for multiple myeloma.

  2002cited by this paper
• Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression

  2002cited by this paper
• Blood donor leukocyte reduction filters as a source of human B lymphocytes.

  2001cited by this paper
• Apoptosis‐associated release of Smac/DIABLO from mitochondria requires active caspases and is blocked by Bcl‐2

  2001cited by this paper
• Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia.

  2000cited by this paper
• Structure Activity Relationships of Antiproliferative Rocaglamide Derivatives from Aglaia Species (Meliaceae)

  1999cited by this paper
• 1H-Cyclopenta[b]benzofuran Lignans from Aglaia Species Inhibit Cell Proliferation and Alter Cell Cycle Distribution in Human Monocytic Leukemia Cell Lines

  1999cited by this paper
• Therapeutic compounds and methods

  1999cited by this paper
• Cytotoxic and antiplatelet aggregation principles from Aglaia elliptifolia.

  1997cited by this paper
• MCL‐1, a member of the BCL‐2 family, is induced rapidly in response to signals for cell differentiation or death, but not to signals for cell proliferation

  1996cited by this paper
• In vivo drug screening applications of HIV-infected cells cultivated within hollow fibers in two physiologic compartments of mice.

  1995cited by this paper
• Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.

  1991cited by this paper
• Correlation of in vitro cytotoxicity with preclinical in vivo antitumor activity.

  1988cited by this paper
• Correlation of in vitro cytotoxicity with preclinical in vivo antitumor activity.

  1988cited by this paper
• X-Ray crystal structure of rocaglamide, a novel antileulemic 1H-cyclopenta[b]benzofuran from Aglaia elliptifolia

  1982cited by this paper
• A Simple Sequentially Rejective Multiple Test Procedure

  1979cited by this paper
• Silvestrol Regulates G 2 / M Checkpoint Genes Independent of p 53 Activity

  year unknowncited by this paper

• The continuing need for taxonomic input in phytochemical research.

  2025cites this paper
• Silvestrol inhibits nasopharyngeal carcinoma cells and synergizes with CX-5461: Insights from a proteomics study

  2025cites this paper
• Silvestrol, a potent anticancer agent with unfavourable pharmacokinetics: Current knowledge on its pharmacological properties and future directions for the development of novel drugs.

  2024cites this paper
• DMDA-PatA mediates RNA sequence-selective translation repression by anchoring eIF4A and DDX3 to GNG motifs

  2024cites this paper
• Potent anti-coronaviral activity of pateamines and new insights into their mode of action

  2024cites this paper
• Medicinal chemistry approaches to target the MNK-eIF4E axis in cancer.

  2023cites this paper
• Phytocompounds as a source for the development of new drugs to treat respiratory viral infections

  2023cites this paper
• Comparing the Effects of Rocaglates on Energy Metabolism and Immune Modulation on Cells of the Human Immune System

  2023cites this paper
• RNA-binding proteins in cancer drug discovery.

  2023cites this paper
• Study on the inhibitory effect of rocaglamide against Micropterus salmoides rhabdovirus (MSRV)

  2023cites this paper
• Synthetic flavagline derivative 1‐chloroacetylrocaglaol promotes apoptosis in K562 erythroleukemia cells through miR‐17‐92 cluster genes

  2022cites this paper
• EIF4A inhibition targets bioenergetic homeostasis in AML MOLM-14 cells in vitro and in vivo and synergizes with cytarabine and venetoclax

  2022cites this paper
• In Vitro Safety, Off-Target and Bioavailability Profile of the Antiviral Compound Silvestrol

  2022cites this paper
• A parasitic fungus employs mutated eIF4A to survive on rocaglate-synthesizing Aglaia plants

  2022cites this paper
• Compounds for selective translational inhibition.

  2022cites this paper
• Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia

  2022cites this paper
• Pharmacological modulation of Kv1.3 potassium channel selectively triggers pathological B lymphocyte apoptosis in vivo in a genetic CLL model

  2022cites this paper
• Pediatric acute lymphoblastic leukemia management using multitargeting bioactive natural compounds: A systematic and critical review.

  2022cites this paper
• Cytotoxic and Apoptotic Activity of Aglaforbesin Derivative Isolated from Aglaia loheri Merr. on HCT116 Human Colorectal Cancer Cells

  2021cites this paper
• Comparative phytochemistry of flavaglines (= rocaglamides), a group of highly bioactive flavolignans from Aglaia species (Meliaceae)

  2021cites this paper
• Strategies targeting FLT3 beyond the kinase inhibitors.

  2021cites this paper
• Update on Phytochemical and Biological Studies on Rocaglate Derivatives from Aglaia Species

  2021cites this paper
• Inhibitors of Eukaryotic Translational Machinery as Therapeutic Agents.

  2021cites this paper
• CD38-Directed Vincristine Nanotherapy for Acute Lymphoblastic Leukemia.

  2021cites this paper
• Proteomics reveal cap-dependent translation inhibitors remodel the translation machinery and translatome

  2021influential citation
• A forward genetic screen identifies modifiers of rocaglate responsiveness

  2021cites this paper
• Targeted inhibition of eIF4A suppresses B-cell receptor-induced translation and expression of MYC and MCL1 in chronic lymphocytic leukemia cells

  2021cites this paper
• The rocaglate CR-31-B (−) inhibits SARS-CoV-2 replication at non-cytotoxic, low nanomolar concentrations in vitro and ex vivo

  2020cites this paper
• Current status and contemporary approaches to the discovery of antitumor agents from higher plants.

  2020cites this paper
• Natural antiviral compound silvestrol modulates human monocyte‐derived macrophages and dendritic cells

  2020cites this paper
• Transcription and Translation Inhibitors in Cancer Treatment

  2020cites this paper
• The multifaceted functions of RNA helicases in the adaptive cellular response to hypoxia: From mechanisms to therapeutics.

  2020cites this paper
• Targeted inhibition of mRNA translation initiation factors as a novel therapeutic strategy for mature B-cell neoplasms

  2020cites this paper
• AMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic Leukemia

  2020cites this paper
• Oxo-aglaiastatin-Mediated Inhibition of Translation Initiation

  2019cites this paper
• Growth suppression of human oral cancer cells by candidate agents for cetuximab‐side effects

  2019cites this paper
• Promising Terpenes as Natural Antagonists of Cancer: An In-Silico Approach

  2019cites this paper
• Targeting Protein Translation by Rocaglamide and Didesmethylrocaglamide to Treat MPNST and Other Sarcomas

  2019cites this paper
• Prohibitin (PHB) expression is associated with aggressiveness in DLBCL and flavagline-mediated inhibition of cytoplasmic PHB functions induces anti-tumor effects

  2019cites this paper
• Structurally Modified Cyclopenta[b]benzofuran Analogues Isolated from Aglaia perviridis.

  2019cites this paper
• Translating from cancer to the brain: regulation of protein synthesis by eIF4F

  2019cites this paper
• Targeting Oncogenic Protein Sythesis in MYC-driven B Cell Lymphoma

  2019cites this paper
• Targeting Translation of mRNA as a Therapeutic Strategy in Cancer

  2019cites this paper
• Targeting Translation Initiation by Synthetic Rocaglates for Treating MYC-driven Lymphomas

  2019cites this paper
• Cytostatic and Cytotoxic Natural Products against Cancer Cell Models

  2019cites this paper
• The natural compound silvestrol inhibits hepatitis E virus (HEV) replication in vitro and in vivo

  2018cites this paper
• The Search for Anticancer Agents from Tropical Plants.

  2018cites this paper
• Inhibition of Zika Virus Replication by Silvestrol

  2018cites this paper
• The prohibitin-binding compound fluorizoline induces apoptosis in chronic lymphocytic leukemia cells ex vivo but fails to prevent leukemia development in a murine model

  2018influential citation
• Burkholderia Lethal Factor 1, a Novel Anti-Cancer Toxin, Demonstrates Selective Cytotoxicity in MYCN-Amplified Neuroblastoma Cells

  2018cites this paper
• Chemical and CRISPR/Cas9 Tools for Functional Characterization of RNA Helicases

  2018cites this paper
• Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms

  2018cites this paper
• Broad-spectrum antiviral activity of the eIF4A inhibitor silvestrol against corona- and picornaviruses

  2017cites this paper
• The natural compound silvestrol is a potent inhibitor of Ebola virus replication

  2017cites this paper
• The prohibitin-binding compound fluorizoline induces apoptosis in chronic lymphocytic leukemia cells through the upregulation of NOXA and synergizes with ibrutinib , AICAR or venetoclax

  2017cites this paper
• The prohibitin-binding compound fluorizoline induces apoptosis in chronic lymphocytic leukemia cells through the upregulation of NOXA and synergizes with ibrutinib, 5-aminoimidazole-4-carboxamide riboside or venetoclax

  2017cites this paper
• Herbal Compounds as Potential Anticancer Therapeutics : Current

  2017cites this paper
• Article title: Inhibiting CARD11 translation during BCR activation by targeting the eIF4A RNA helicase

  2017cites this paper
• Drugs under preclinical and clinical study for treatment of acute and chronic lymphoblastic leukemia

  2016cites this paper
• Translation Initiation Factors: Reprogramming Protein Synthesis in Cancer.

  2016cites this paper
• Silvestrol induces early autophagy and apoptosis in human melanoma cells

  2016cites this paper
• Inhibition of nasopharyngeal carcinoma cell proliferation and synergism of cisplatin with silvestrol and episilvestrol isolated from Aglaia stellatopilosa

  2016cites this paper
• Cytotoxic Rocaglate Derivatives from Leaves of Aglaia perviridis

  2016cites this paper
• Components of the eIF4F complex are potential therapeutic targets for malignant peripheral nerve sheath tumors and vestibular schwannomas.

  2016cites this paper
• Total synthesis of a biotinylated rocaglate: Selective targeting of the translation factors eIF4AI/II.

  2016cites this paper
• Hippuristanol - A potent steroid inhibitor of eukaryotic initiation factor 4A

  2016cites this paper
• Cyclopenta[b]benzofuran and Secodammarane Derivatives from the Stems of Aglaia stellatopilosa.

  2016cites this paper
• Substrate Specificity of Aglaia loheri Active Isolate towards P-glycoprotein in Multidrug-Resistant Cancer Cells

  2016cites this paper
• mTOR, Aging, and Cancer: A Dangerous Link

  2016cites this paper
• Identifying and Targeting Immune Escape Mechanisms in Epstein-Barr Virus-Driven Lymphoproliferative Disease

  2016cites this paper
• Small molecules targeting Mcl-1: the search for a silver bullet in cancer therapy

  2016cites this paper
• Résistances/sensibilisations aux anti-CD20 (rituximab) dans les lymphomes diffus à grandes cellules B (DLBCL)

  2016cites this paper
• Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation.

  2016cites this paper
• Discovery of Anticancer Agents of Diverse Natural Origin.

  2016cites this paper
• Strategies targeting apoptosis proteins to improve therapy of chronic lymphocytic leukemia.

  2015cites this paper
• Bioactive Flavaglines: Synthesis and Pharmacology

  2015cites this paper
• Natural Products and Cancer Stem Cells.

  2015cites this paper
• Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia

  2015cites this paper
• Translation Inhibition by Rocaglates Is Independent of eIF4E Phosphorylation Status

  2015cites this paper
• T-ALL: ALL a matter of Translation?

  2015cites this paper
• The long journey of TCL1 transgenic mice: lessons learned in the last 15 years.

  2015cites this paper
• Targeting the eIF4F translation initiation complex: a critical nexus for cancer development.

  2015cites this paper
• Molecular mechanisms and anti‐cancer aspects of the medicinal phytochemicals rocaglamides (=flavaglines)

  2015cites this paper
• ENDEMIC PLANTS FROM MAURITIUS ISLANDS AS POTENTIAL ANTICANCER BIORESOURCES

  2015cites this paper
• Targeting the eIF4A RNA helicase as an anti-neoplastic approach.

  2015cites this paper
• HOMOHARRINGTONINE: A NASCENT PHYTOCHEMICAL FOR CANCER TREATMENT (A REVIEW)

  2015cites this paper
• eIF4A1 is a promising new therapeutic target in ER-negative breast cancer

  2015cites this paper
• Inhibition of ER stress-associated IRE-1/XBP-1 pathway reduces leukemic cell survival.

  2014cites this paper
• Rocaglamide, silvestrol and structurally related bioactive compounds from Aglaia species.

  2014cites this paper
• Flavaglines target primitive leukemia cells and enhance anti-leukemia drug activity

  2014influential citation
• title : Inhibiting CARD 11 translation during BCR activation by targeting the eIF 4 A RNA helicase Short title : BCR activation enhances eIF 4 A activity

  2014cites this paper
• Homoharringtonine and omacetaxine for myeloid hematological malignancies

  2014cites this paper
• The translation inhibitor silvestrol exhibits direct anti-tumor activity while preserving innate and adaptive immunity against EBV-driven lymphoproliferative disease

  2014cites this paper
• Transcriptome-wide characterization of the eIF4A signature highlights plasticity in translation regulation

  2014cites this paper
• Simplified Silvestrol Analogues with Potent Cytotoxic Activity

  2014cites this paper
• LYMPHOID NEOPLASIA Inhibiting CARD 11 translation during BCR activation by targeting the eIF 4 A RNA helicase

  2014cites this paper
• Targeting translation initiation in breast cancer

  2014cites this paper
• Mouse models in the study of chronic lymphocytic leukemia pathogenesis and therapy.

  2014cites this paper
• Current and Emerging Therapies Targeting Translation

  2014cites this paper
• Investigating the cellular mechanisms that determine RNMT dependency in breast cancer cells

  2014cites this paper